The aim of this study is to identify correlations between change from the baseline at Month 24 in Forced Vital Capacity (FVC) (% predicted and mL) and change from the baseline at Month 24 in cough or dyspnoea scores [points] as measured in the living with pulmonary fibrosis questionnaire (L-PF) over 24 months of nintedanib treatment in patients with connective tissues disease-associated progressive fibrosing interstitial lung disease (CTD associated PF-ILD) under routine clinical practice conditions in Greece.
Athens 10676, Greece
Private physician Dr. Katsifis
Athens 11362, Greece
General Hospital of Athens "Ippokrateio"
Athens 11527, Greece
General Hospital of Athens "Laiko"
Athens 11527, Greece
Private physician Dr. Karageorgas
Athens 11634, Greece
University General Hospital ATTIKON
Athens 12462, Greece
General Hospital KAT
Athens 14561, Greece
University General Hospital of Heraklion
Heraklion 71003, Greece
Private physician Dr. Georgiadis
Ioannina 45332, Greece
Private physician Prof. Sakkas
Larisa 41222, Greece
University General Hospital of Larisa
Larisa 41334, Greece
Private physician Dr. Iliadou
Nea Smirni, Athens 17121, Greece
General Hospital of Thessaloniki "Hippokration"
Thessaloniki 54642, Greece
Age ≥18 years with a confirmed physician diagnosis of connective tissue disease (CTD) associated Progressive Fibrosing Interstitial Lung Disease (PF-ILD)
Have been prescribed nintedanib according to the local Summary of Product Characteristics (SmPC) and clinical judgment. Therapy with nintedanib must have been started for clinical reasons independently from the intended patient enrolment into the study at a maximum of 15 days before enrolment into the trial.
Patients currently receiving treatment with any investigational drug/device/intervention or who have received any investigational product within 1 month or 5 half-lives of the investigational agent (whichever is longer) before the commencement of therapy with nintedanib
Patients at baseline with a known condition or reason that will result in withdrawal from the study before the 24-month time point
Pregnancy or lactation
Study Contact Info
Contact Listings Owner Form
Correlation Between Changes in Lung Function and Changes in Cough and Dyspnoea in Nintedanib-treated Connective Tissue Disease Interstitial Lung Disease (CTD-ILD) Patients 0 reviewsWrite Your Review
There are no reviews yet.